Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 23rd International Conference on Advanced Materials & Nanotechnology Tokyo, Japan.

Day 1 :

Keynote Forum

Amany A Mostafa

National Research Center, Egypt

Keynote: Sustained drug release scaffolds as bone implants

Time : 09:05-10:05 AM

OMICS International Advanced Materials-Japan-2019 International Conference Keynote Speaker Amany A Mostafa photo

Professor Amany Mostafa has completed her PhD from Cairo University and postdoctoral studies from GeorgiaTech University, Petite Parker Institute for Bioscience & Bioengineering. She is currently the Head of Inorganic Chemical Industries & Mineral Resources Division at the National Research Centre, Egypt. She manged many International Projects. Her research interests are focused on Materials Science and Nanotechnology and their applications in industry as well as the medical research area. Her expertise has been developed as part of a long standing interdisciplinary collaborative work in nanomaterials used for Regenerative Medicine: Biomaterials, Drug delivery and Tissue engineering.


The current work presents the fabrication of newly designed scaffolds from mixture of chitosan (CS) / polyvinyl alcohol (PVA) and bioactive glass (CS/PVA-G) loaded with an antiosteoporotic drug; risedronate sodium for bone regeneration. The scaffolds were formulated using Freeze drying technique utilizing a mixture of two types of polymers. The prepared scaffolds were then characterized regarding their porosity and the in-vitro drug release pattern. The selected bioactive glasses and the scaffolds were subjected for an in vitro cell evaluation and in vivo experimental animal studies either in rats or in dogs. The results showed that the particle size of the prepared nanobioactive glass by modified sol-gel technique ranging between 5.9-13.7 nm. The prepared scaffolds show that the presence of CS and BG resulted in higher porosity while the addition of drug lowered the porosity percent. The in vitro release study proves the sustained drug release profile of the tested scaffolds up to two months. Tensile testing of the selected scaffolds showed that adding 10% BG resulted in scaffolds of higher strength and stiffness compared to 30%BG. In vitro cell tests of the scaffolds reveal higher proliferation level of the Saos-2 cells on medicated formulations than their counter part formulations without risedronate. In vivo post-operative radiographs in critical-sized mandibular bone defect in dogs revealed induced bone after 10 weeks. Therefore, the CS/PVA-G scaffolds are safe and useful materials against osteoporosis and could be used for bone regeneration.